ClinicalTrials.gg
WithdrawnNCT06068881MandolinUpdated Jan 30, 2026

A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation

A Phase 2 interventional study of Tazverik (Tazemetostat) in Follicular Lymphoma and Refractory Follicular Lymphoma, sponsored by Epizyme, Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Epizyme, Inc. (part of Ipsen) · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
Never started

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing tazemetostat in Lymphoma, Follicular — none open to participants now, 5 under way, 1 of them phase 3. tazemetostat · Lymphoma, Follicular.

Enrollment
13th of 14
0 · median 27
Started
2025
with 1 other
Phase 2
4 of 14
none open now
Registered
13th of 14
by date
Lead sponsor
6 of 14
Epizyme, Inc.

Among the 14 studies testing tazemetostat in Lymphoma, Follicular, this one is the 13th largest by enrollment, is one of 2 that started in 2025, is one of 4 in phase 2, and was the 13th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

None of the 14 studies testing tazemetostat in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →

About tazemetostat

tazemetostat: first FDA approval 2020 (TAZVERIK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing tazemetostat in Lymphoma, Follicular as a file.
02

Study summary

The purpose of this research study is to learn about the effectiveness and safety of the study drug, tazemetostat, in adults with relapsed/refractory follicular lymphoma whose tumours do not have an "EZH2 gain-of-function" genetic mutation. Follicular lymphoma is a blood cancer. It affects white blood cells called lymphocytes. White blood cells normally help to fight infections, but when you have follicular lymphoma, the blood cells can form tumours in your body. 'Relapsed/refractory' follicular lymphoma means the disease has either not improved or is getting worse (progressing) during or after previous treatment.

Tazemetostat already has approval in the United States for the treatment of adult patients with relapsed/refractory follicular lymphoma with or without the "EZH2" mutation who have no satisfactory alternative treatment options.

This study is being conducted to better understand the effectiveness in patients whose tumours do not have an "EZH2 gain-of-function" genetic mutation and who previously received therapies commonly used in the U.S. in your body.

'Relapsed/refractory' follicular lymphoma means the disease has either not improved or is getting worse (progressing) during or after previous treatment.

Tazemetostat already has approval in the United States for the treatment of adult patients with relapsed/refractory follicular lymphoma with or without the "EZH2 gain-of-function" mutation who have no satisfactory alternative treatment options. This study is being conducted to better understand the effectiveness in patients whose tumours do not have an "EZH2" genetic mutation and who previously received therapies commonly used in the U.S.

In this study, all participants will receive the study drug. It will be taken by mouth (orally), as a tablet, twice daily. The sizes and number of tumours according to scan results will be collected as well as results of safety tests (such as physical examinations and laboratory tests).

The study consists of 4 periods:

  • Screening period may take up to 4 weeks and require at least 1 visit.
  • Treatment period will require 2 visits for each of the first 2 months, followed by 1 visit every month for the remainder of the first 12 months, followed by 1 visit every 3 months (except for women of childbearing potential [WOCBP], who will continue to have a pregnancy testing every month) until unacceptable toxicity, disease progression, or the start of new systemic anticancer therapy, whichever is first.
  • Safety follow-up period will last for 1 month after the last dose of tazemetostat, and it will end with 1 visit or telephone call.
  • Long-term follow-up period is only for participants who stop taking tazemetostat while their disease continues to respond; this period will last until disease progression, start of new cancer treatment, or death from any cause, whichever is first, and will require a visit every 3 months.

Tazemetostat will be provided to participants who tolerate it for as long as their disease does not progress.

Participants may be transferred to another study or program after about 2 years for continued treatment with tazemetostat or for long-term follow-up. Patients may withdraw consent to participate at any time.

03

Conditions studied

  • Follicular Lymphoma
  • Refractory Follicular Lymphoma

Keywords

  • EZH2 Gain-of-function
  • EZH2 GoF
  • Tazemetostat
  • Follicular Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age, inclusive, at the time of signing the form
  • confirmed follicular lymphoma (FL) grades 1, 2, or 3A
  • Previously treated with ≥1 prior systemic chemotherapy, immunotherapy, or chemo-immunotherapy consistent with those used in a US population, including but not limited to bendamustine, obinutuzumab, rituximab plus lenalidomide. Patients with only 1 should not be eligible for available combination or monotherapies
  • Documented , refractory, or progressive disease (PD) after treatment with systemic therapy (refractory defined as less than PR or as PD \<6 months after last dose)

    • as defined by Lugano Classification
    • Have provided sufficient tumour tissue block or unstained slides for EZH2 mutation and copy number gain (CNG) testing
  • Wild-type EZH2 (ie, lacking GOF mutation). Note: If EZH2 GOF mutation status is known from site specific testing, WT patients can be enrolled with documentation of the testing, and additional or fresh lymph node biopsy taken before starting tazemetostat will be required for confirmatory testing of EZH2 GOF mutation status at study-specific laboratories. If EZH2 GOF mutation status is unknown, the results of central testing confirming wild-type (WT) EZH2 mutation status on an archival tumour sample, or a fresh lymph node biopsy is required before enrolment. (Archival tumour tissue collected within 15 months before the first dose is preferred, where feasible.)
  • (ECOG) performance status ≤2
  • Adequate time between prior anticancer therapy and first dose of tazemetostat as follows:

    • Cytotoxic chemotherapy: At least 21 days.
    • Noncytotoxic chemotherapy (eg, small molecule inhibitor): At least 14 days.
    • Monoclonal and/or bispecific antibodies or chimeric antigen receptor (CAR) T: At least 28 days.
    • Radiotherapy: At least 6 weeks from prior radioisotope therapy; at least 12 weeks from 50% pelvic or total body irradiation.
  • Adequate liver function, by all of the following criteria:

    • Total ≤1.5 × the (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome.
    • Alkaline phosphatase (ALP) (in the absence of bone disease), (ALT), and aspartate aminotransferase (AST) ≤3 × ULN (≤5 × ULN if the patient has liver ).
  • Adequate renal function: Calculated ≥30 mL/minute per the Cockcroft and Gault formula

    • Adequate bone marrow function, by all of the following criteria:
    • (ANC) ≥1000/mm3 (≥1.0 × 109/L) if no lymphoma infiltration of bone marrow OR ANC ≥750/mm3 (≥0.75 × 109/L) with bone marrow infiltration: Without growth factor support (filgrastim or pegfilgrastim) for at least 14 days.
    • ≥75,000/mm3 (≥75 × 109/L), evaluated at least 7 days after last platelet transfusion.
    • ≥9.0 g/dL, though may receive transfusion
  • Adequate coagulation, by both of the following criteria (NOTE: In patients with thromboembolism risk, prophylactic anticoagulation, or antiplatelet therapy at investigator discretion, is recommended):
  • (INR) ≤1.5 × ULN
  • Activated partial thromboplastin time (aPTT) ≤1.5 × ULN (unless on warfarin, then INR ≤3.0).
  • Women of (WOCBP) must have 2 negative pregnancy tests (beta-human chorionic gonadotropin [β-hCG] on-site urine or serum tests with a minimum sensitivity of 25 mIU/mL or equivalent units of β-hCG) during screening. The second of these screening pregnancy tests

Exclusion criteria

Exclusion Criteria:

  • Grade 3b FL, mixed histology FL, or FL that has histologically transformed to DLBCL.
  • other than FL.
  • Any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or myeloproliferative neoplasm (MPN)
  • Any prior history of T-cell lymphoblastic lymphoma (LBL)/T-cell acute lymphoblastic leukaemia (ALL)
  • Major surgery within 4 weeks before the first dose of study intervention.
  • Significant cardiovascular impairment.
  • Prolongation of interval using Fridericia's formula (QTcF) to ≥480 msec at screening or history of long QT syndrome
  • Venous thrombosis or pulmonary embolism within 3 months before starting tazemetostat. Note: Patients with deep vein thrombosis/pulmonary embolism greater than 3 months before treatment are eligible but recommended to receive prophylaxis
  • Uncontrolled active infection requiring systemic therapy
  • Active viral infection with (HIV)
  • History of or C, unless they have adequate liver function as defined by inclusion criteria and are hepatitis B surface antigen negative with undetectable hepatitis B virus (HBV) DNA and/or have undetectable virus (HCV) ribonucleic acid (RNA) if HCV antibody positive
  • History of solid organ transplant
  • Prior exposure to tazemetostat or other inhibitor(s) of EZH2
  • Taking medications that are known strong inhibitors and strong or moderate CYP3A inducers (including St. John's wort)
  • Pregnant or lactating/breastfeeding
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Tazverik (Tazemetostat)

    800mg tablet orally twice daily in continuous 28-day cycles

    Drug: Tazverik (Tazemetostat)

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) assessed by an independent review committee (IRC)

    Defined as complete response + partial response \[CR + PR\]) in response-evaluable participants as assessed by a blinded independent review committee (BIRC).

    Time frame: From baseline to 4 months post last treatment (up to a maximum of 5 years)

Secondary outcomes

  1. ORR assessed by the Investigator

    Time frame: From baseline to 4 months post last treatment (up to a maximum of 5 years)

  2. The Best Overall Response (BOR)

    BOR as assessed by Investigator and by a BIRC.

    Time frame: From baseline to 4 months post last treatment (up to a maximum of 5 years)

  3. Duration Of Response (DOR)

    DOR in participants with an objective response (CR or PR), as assessed by Investigator and by an IRC.

    Time frame: From baseline to 4 months post last treatment (up to a maximum of 5 years)

  4. Progression-free survival (PFS)

    PFS from the date of the first dose of tazemetostat to the date of objective disease progression as assessed by Investigator and an IRC or to the death due to any cause, whichever occurs first.

    Time frame: From baseline to 4 months post last treatment (up to a maximum of 5 years)

  5. Disease Control Rate (DCR)

    DCR (CR + PR + Stable Disease (SD)) in response evaluable participants as assessed by Investigator and an IRC.

    Time frame: From baseline to 4 months post last treatment (up to a maximum of 5 years)

  6. Percentage of participants who experience adverse events (AEs)

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The clinical significance will be graded by the investigator.

    Time frame: From baseline to 4 months post last treatment (up to a maximum of 5 years)

  7. Percentage of Participants with clinically significant changes in laboratory parameters.

    Percentage of participants with clinically significant changes laboratory parameters (blood chemistry, hematology) will be reported. The clinical significance will be graded by the investigator.

    Time frame: From baseline to 4 months post last treatment (up to a maximum of 5 years)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Apr 2029, 43 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2023
First posted
Oct 5, 2023
StartEst.
Sep 2, 2025
Primary completionEst.
Apr 6, 2029
CompletionEst.
Apr 6, 2029
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06068881
Lead sponsor
Epizyme, Inc.
Collaborators
Ipsen
Responsible party
Sponsor
First posted
Oct 5, 2023
Start date
Sep 2, 2025 (estimated)
Primary completion
Apr 6, 2029 (estimated)
Completion
Apr 6, 2029 (estimated)
Last update
Jan 30, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tazemetostat

Start the discussion